Evidence map›Paper›PMID 21859302›Full record

ArticleFuture medicinal chemistry2011

Drug discovery for neglected tropical diseases at the Sandler Center.

Stephanie A Robertson, Adam R Renslo

Abstract read
In one paragraph

Article in Future medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Stephanie A RobertsonSandler Center for Drug Discovery, Department of Pharmaceutical Chemistry, University of California, 600 16th Street, S-272, San Francisco, CA 94158, USA. stephanie.robertson@ucsf.edu
Adam R Renslo

Funding

X-RAY CRYSTALLOGRAPHYP01AI035707 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROUSH, WILLIAM R · 1995 to 2008
$7.8M
NIAID NIH HHS P01 AI035707
6 · The paper itself

Abstract

The Sandler Center's approach to target-based drug discovery for neglected tropical diseases is to focus on parasite targets that are homologous to human targets being actively investigated in the pharmaceutical industry. In this way we attempt to use both the know-how and actual chemical matter from other drug-development efforts to jump start the discovery process for neglected tropical diseases. Our approach is akin to drug repurposing, except that we seek to repurpose leads rather than drugs. Medicinal chemistry can then be applied to optimize the leads specifically for the desired antiparasitic indication.

Indexed as

14-alpha Demethylase InhibitorsAcademies and InstitutesBinding SitesCrystallography, X-RayCysteine EndopeptidasesDrug DesignDrug Evaluation, PreclinicalHumansNeglected DiseasesProtease InhibitorsProtein KinasesProtozoan ProteinsRNA InterferenceSterol 14-Demethylase14-alpha Demethylase Inhibitorscruzain, Trypanosoma cruziCysteine EndopeptidasesProtease InhibitorsProtein KinasesProtozoan ProteinsSterol 14-Demethylase

Identifiers

PMID21859302
PMCPMC3199145

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.